Cargando…

614. Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections and Bacteremia in Infectious Disease Outpatient Infusion Clinics

BACKGROUND: Long-acting lipoglycopeptides (LGPs) are approved for the treatment of acute bacterial skin and skin-structure infections. Broad Gram-positive coverage and weekly dosing regimens are useful for other diagnoses, but real-world data supporting such use are sparse. We review our experience...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metzger, Brian S, Prokesch, Richard C, Bernett, Jorge R, Mandel, Richard M, Nathan, Ramesh V, Stock, Kent, Hardin, Thomas C, Schroeder, Claudia P, Van Anglen, Lucinda J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776532/ http://dx.doi.org/10.1093/ofid/ofaa439.808

Ejemplares similares

313. Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis
por: Metzger, Brian S, et al.
Publicado: (2018)

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2020)

755 Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs Traditional Home Health Care (HHC)
por: Prokesch, Richard C., et al.
Publicado: (2014)

597. The Impact of COVID-19 on Outpatient Intravenous Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers (POICs)
por: Martin, Clifford P, et al.
Publicado: (2021)

750. Serious Bacterial Infections: Successful Outpatient Management by Infectious Disease Physicians in Office Infusion Centers
por: Adams, John S, et al.
Publicado: (2019)

2494. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)
por: Prokesch, Richard C, et al.
Publicado: (2019)

763 Low Hospital Admission Rates Following Physician Office Infusion Center (POIC)-Based Outpatient Treatment with Intravenous Antibiotics (IVABs)
por: Alvarado, Fernando S., et al.
Publicado: (2014)

598. A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)
por: Hengel, Richard L, et al.
Publicado: (2021)

2081. Low 30-Day Hospital Readmission Rates in Medicare Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers
por: Luu, Quyen, et al.
Publicado: (2019)

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers
por: Hengel, Richard L, et al.
Publicado: (2018)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

Successful Establishment of an Antimicrobial Stewardship Program (ASP) for Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Nathan, Ramesh V, et al.
Publicado: (2017)

1854. Effective Antimicrobial Stewardship for Outpatient Parenteral Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Disease Physician Infusion Centers
por: Nathan, Ramesh V, et al.
Publicado: (2018)

Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population
por: Van Anglen, Lucinda J, et al.
Publicado: (2017)

2367. Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2018)

2382. Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
por: Garey, Kevin W, et al.
Publicado: (2019)

2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)
por: Luu, Quyen, et al.
Publicado: (2018)

1016. Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2022)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

Long-Acting Lipoglycopeptides for Gram-Positive Bacteremia at the End of Life to Facilitate Hospice Care: A Report of 3 Cases
por: Datta, Rupak, et al.
Publicado: (2018)

Specific Inhibition of VanZ-Mediated Resistance to Lipoglycopeptide Antibiotics
por: Sur, Vishma Pratap, et al.
Publicado: (2021)

610. Low Rates of Acute Kidney Injury (AKI) in Outpatient Vancomycin Managed by Pharmacists using Precision Dosing Software
por: Schroeder, Claudia P, et al.
Publicado: (2022)

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life
por: Hengel, Richard L., et al.
Publicado: (2022)

Staphylococcus aureus is able to generate resistance to novel lipoglycopeptide antibiotic gausemycin A
por: Poshvina, Darya V., et al.
Publicado: (2022)

Engineered biosynthesis of enduracidin lipoglycopeptide antibiotics using the ramoplanin mannosyltransferase Ram29
por: Wu, Ming-Cheng, et al.
Publicado: (2015)

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

231. Retrospective Comparison of Intravenous Therapy, Oral Therapy, and Lipoglycopeptides for the Treatment of Osteomyelitis
por: Stumphauzer, Alex, et al.
Publicado: (2021)

Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
por: Smith, Jordan R., et al.
Publicado: (2015)

Long-Acting Lipoglycopeptides: “Lineless Antibiotics” for Serious Infections in Persons Who Use Drugs
por: Morrisette, Taylor, et al.
Publicado: (2019)

VanZ Reduces the Binding of Lipoglycopeptide Antibiotics to Staphylococcus aureus and Streptococcus pneumoniae Cells
por: Vimberg, Vladimir, et al.
Publicado: (2020)

MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide
por: Du, Jing-Jing, et al.
Publicado: (2022)

617. Long Acting Lipoglycopeptide Use in Veterans for Serious Gram-Positive Infections in the COVID Era
por: Saldana, Carlos S, et al.
Publicado: (2021)

Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection
por: Konicek, Donna M., et al.
Publicado: (2023)

Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections
por: Plaunt, Adam J., et al.
Publicado: (2021)

Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear
por: Grubaugh, Nathan D., et al.
Publicado: (2020)

Structure and Biosynthesis of Desmamides A–C, Lipoglycopeptides from the Endophytic Cyanobacterium Desmonostoc muscorum LEGE 12446
por: Freitas, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jgqb1ont7gtjmlpaf4196romue